Medicinal mushroom modulators of molecular targets as cancer therapeutics

被引：375
作者：
Zaidman, BZ
Yassin, M
Mahajna, J
Wasser, SP
机构：
[1] Migal Galilee Technol Ctr, IL-11061 Kiryat Shmona, Israel
[2] Univ Haifa, Inst Evolut, Biodivers & Biotechnol Ctr Cryptogam Plants & Fun, IL-31905 Haifa, Israel
来源：
APPLIED MICROBIOLOGY AND BIOTECHNOLOGY | 2005年 / 67卷 / 04期
关键词：
D O I：
10.1007/s00253-004-1787-z
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Empirical approaches to discover anticancer drugs and cancer treatments have made limited progress in the past several decades in finding a cure for cancer. The expanded knowledge of the molecular basis of tumorigenesis and metastasis, together with the inherently vast structural diversity of natural compounds found in mushrooms, provided unique opportunities for discovering new drugs that rationally target the abnormal molecular and biochemical signals leading to cancer. This review focuses on mushroom low-molecular-weight secondary metabolites targeting processes such as apoptosis, angiogenesis, metastasis, cell cycle regulation, and signal transduction cascades. Also discussed in this review are high-molecular-weight polysaccharides or polysaccharide-protein complexes from mushrooms that appear to enhance innate and cell-mediated immune responses, exhibit antitumor activities in animals and humans, and demonstrate the anticancer properties of selenium compounds accumulated in mushrooms.
引用
收藏
页码：453 / 468
页数：16
相关论文
共 181 条
  • [1] Characterization of β-glucan recognition site on C-type lectin, dectin 1
    Adachi, Y
    Ishii, T
    Ikeda, Y
    Hoshino, A
    Tamura, H
    Aketagawa, J
    Tanaka, S
    Ohno, N
    [J]. INFECTION AND IMMUNITY, 2004, 72 (07) : 4159 - 4171
  • [2] ADACHI Y, 1994, BIOL PHARM BULL, V17, P1554, DOI 10.1248/bpb.17.1554
  • [3] Review of estrone sulfatase and its inhibitors - An important new target against hormone dependent breast cancer
    Ahmed, S
    Owen, CP
    James, K
    Sampson, L
    Patel, CK
    [J]. CURRENT MEDICINAL CHEMISTRY, 2002, 9 (02) : 263 - 273
  • [4] Dehydrotrametenonic acid and dehydroeburiconic acid from Poria cocos and their inhibitory effects on eukaryotic DNA polymerase α and β
    Akihisa, T
    Mizushina, Y
    Ukiya, M
    Oshikubo, M
    Kondo, S
    Kimura, Y
    Suzuki, T
    Tai, T
    [J]. BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY, 2004, 68 (02) : 448 - 450
  • [5] Antiviral activity of Inonotus hispidus
    Ali, NAA
    Mothana, RAA
    Lesnau, A
    Pilgrim, H
    Lindequist, U
    [J]. FITOTERAPIA, 2003, 74 (05) : 483 - 485
  • [6] Inhibition of tumor necrosis factor-α-induced nuclear translocation and activation of NF-κB by dehydroxymethylepoxyquinomicin
    Ariga, A
    Namekawa, J
    Matsumoto, N
    Inoue, J
    Umezawa, K
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (27) : 24625 - 24630
  • [7] Ligand binding to the (1→3)-β-D-glucan receptor stimulates NFκB activation, but not apoptosis in U937 cells
    Battle, J
    Ha, TZ
    Li, CF
    Della Beffa, V
    Rice, P
    Kalbfleisch, J
    Browder, W
    Williams, D
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 249 (02) : 499 - 504
  • [8] Beecken W.-D., 2000, J Cell Mol Med, V4, P262, DOI 10.1111/j.1582-4934.2000.tb00125.x
  • [9] Phase II trial of irofulven (6-hydroxymethylacylfulvene) for patients with advanced renal cell carcinoma
    Berg, WJ
    Schwartz, L
    Yu, R
    Mazumdar, M
    Motzer, RJ
    [J]. INVESTIGATIONAL NEW DRUGS, 2001, 19 (04) : 317 - 320
  • [10] RACK1 is up-regulated in angiogenesis and human carcinomas
    Berns, H
    Humar, R
    Hengerer, B
    Kiefer, FN
    Battegay, EJ
    [J]. FASEB JOURNAL, 2000, 14 (15) : 2549 - 2558
12345678910